2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06
±³À°ÀÏÀÚ : 2024-07-06
±³À°Àå¼Ò : ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç
±³À°ÁÖÁ¦ : 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¹®¸Æ¾ÐÇ×ÁøÁõ ¿¬±¸È¸
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 13:30~13:45 Basic research in portal hypertension ÇÑ¿ëÇö(°¿øÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 13:45~14:00 Clinical research in portal hypertension ±èÁ¤Èñ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 14:00~14:25 Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anto-Hepatic-Fibrosis Therapy ÀÌ¿ëÇö(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 14:25~14:50 Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2 Àӽ¼ø(°è¸íÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 15:05~15:30 MASLD and MetALD increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a Korean nationwide study Á¤¼®¼Û(Â÷ÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 15:30~15:55 Impact of systemic inflammation on ACLF ¼Ûµµ¼±(°¡Å縯ÀÇ´ë)
Åä·Ð 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 15:55~16:05 Panel discussion ÀÌÇö¿õ ±èÁ¤ÇÑ(¿¬¼¼ÀÇ´ë °Ç±¹ÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 16:05~16:30 High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study À±ÁؽÄ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 16:30~16:55 Interventional procedures and research in protal hypertersion Çöµ¿È£(¼¿ïÀÇ´ë)
Åä·Ð 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº ´ë°´ç 16:55~17:05 Panel discussion ¹ÚÁ¤±æ Á¤½Â¿ø(¿µ³²ÀÇ´ë ¼øõÇâÀÇ´ë)